<DOC>
	<DOC>NCT00796913</DOC>
	<brief_summary>ATD therapy for Graves' disease is one of the commonly used options for therapy of the hyperthyroidism. The investigators study how to optimally keep patients in remission.</brief_summary>
	<brief_title>Remission Induction and Sustenance in Graves' Disease 2</brief_title>
	<detailed_description>A detailed description of patients entering the initial observational phase of the study (RISG1) has been published: Laurberg P, Nygaard B, Andersen S, Carl√© A, Karmisholt J, Krejbjerg A, Pedersen IB, Andersen SL. Association between TSH-Receptor Autoimmunity, Hyperthyroidism, Goitre, and Orbitopathy in 208 Patients Included in the Remission Induction and Sustenance in Graves' Disease Study. J Thyroid Res. 2014;2014:165487. doi: 10.1155/2014/165487.</detailed_description>
	<mesh_term>Graves Disease</mesh_term>
	<mesh_term>Hyperthyroidism</mesh_term>
	<criteria>Graves hyperthyroidism in remission after ATD Age &lt; 18, severe concomitant disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
</DOC>